About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
Search
28
2020/08
Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava
™
(eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China
07
2020/08
Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors
22
2020/06
Everest Medicines Announces Positive Results of In Vitro Study of Xerava
™
(eravacycline) Against Human Mycoplasmas
04
2020/06
Everest Medicines Completes US$310 Million Series C Financing
24
2020/04
Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast
22
2020/04
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration to Initiate China Registration Study of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer
17
2020/04
Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections
09
2020/04
Everest Medicines Announces Positive Results from In Vitro Study of Taniborbactam (VNRX-5133) in Combination with Cefepime
17
2020/03
Everest Medicines Forms Strategic Partnership with Jiashan National Economic and Technological Development Zone and Jiashan SDIC
20
2020/02
Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer
15
2019/12
Everest Medicines Announces Approval of Nefecon's Clinical Trial Application by the China National Medical Products Administration
14
2019/11
Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
Copyright Everest Medicines 2020 云顶药业(苏州)有限公司
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
沪公网安备 31010602006477号
a>